Noel Donnelly
Direttore Finanziario/CFO presso PEPGEN INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Noel Donnelly is currently the Chief Financial Officer at PepGen Inc. Prior to this role, he served as the Chief Financial Officer at EIP Pharma, Inc. from 2019 to 2021.
Mr. Donnelly holds an MBA from Babson College and an undergraduate degree from the University of Massachusetts Lowell.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
PEPGEN INC.
-.--% | 31/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Noel Donnelly
| Società | Posizione | Inizio |
|---|---|---|
| PEPGEN INC. | Direttore Finanziario/CFO | 01/10/2021 |
Precedenti posizioni note di Noel Donnelly
| Società | Posizione | Fine |
|---|---|---|
EIP Pharma, Inc.
 EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Direttore Finanziario/CFO | 01/10/2021 |
Formazione di Noel Donnelly
| Babson College | Masters Business Admin |
| University of Massachusetts Lowell | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PEPGEN INC. | Health Technology |
| Aziende private | 1 |
|---|---|
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Noel Donnelly
